Age-standardized death from<unk>  per 100,000 inhabitants in 2004. As of 2012,<unk>  is the second-most frequently diagnosed cancer (at 15% of all male cancers) and the sixth leading cause of cancer death in males worldwide. In 2010,<unk>  resulted in 256,000 deaths, up from 156,000 deaths in 1990. Rates of<unk>  vary widely. Rates vary widely between countries. It is least common in South and East Asia, and more common in Europe, North America, Australia, and New Zealand.<unk>  is least common among Asian men and most common among black men, with white men in between. The average annual incidence rate of<unk>  between 1988 and 1992 among Chinese men in the United States was 15 times higher than that of their counterparts living in Shanghai and Tianjin, but these high rates may be affected by higher rates of detection. Many suggest that<unk>  may be under-reported, yet benign<unk> c hyperplasia incidence in China and Japan is similar to rates in Western countries. More than 80% of men develop<unk>  by age 80. United States New cases and deaths from<unk>  in the United States per 100,000 males between 1975 and 2014<unk>  is the third-leading cause of cancer death in men, exceeded by lung cancer and colorectal cancer. It accounts for 19% of all male cancers and 9% of male cancer-related deaths. Cases ranged from an estimated 230,000 in 2005 to an estimated 164,690 In 2018. Deaths held steady around 30,000 in 2005 and 29,430 in 2018. Age-adjusted incidence rates increased steadily from 1975 through 1992, with particularly dramatic increases associated with the spread of PSA screening in the late 1980s, later followed by a fall in incidence. A decline in early-stage incidence rates from 2011 to 2012 (19%) in men aged 50 years and older persisted through 2013 (6%). Declines in mortality rates in certain jurisdictions may reflect the interaction of PSA screening and improved treatment. The estimated lifetime risk is about 14.0%, and the lifetime mortality risk is 2.6%. Between 2005 and 2011, the proportion of disease diagnosed at a locoregional stage was 93% for whites and 92% for African Americans; the proportion of disease diagnosed at a late stage was 4% for whites and 5% for African Americans.<unk>  is more common in the African American population than the White American population. An autopsy study of White and Asian men also found an increase in occult<unk>  with age, reaching nearly 60% in men older than 80 years. More than 50% of cancers in Asian men and 25% of cancers in White men had a Gleason score of 7 or greater, suggesting that Gleason score may be an imprecise indicator of clinically insignificant cases. Canada<unk>  is the third-leading type of cancer in Canadian men. In 2016, around 4,000 died and 21,600 men were diagnosed with<unk> . Europe In Europe in 2012, it was the third-most diagnosed cancer after breast and colorectal cancers at 417,000 cases. In the United Kingdom, it is the second-most common cause of cancer death after lung cancer, where around 35,000 cases are diagnosed every year, of which around 10,000 are fatal.
Prostate cancer
Benign prostatic hyperplasia
Bladder cancer
Penile cancer
Testicular cancer
Urethral cancer
Breast cancer
Kidney cancer